Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharming's C1 inhibitor granted IND for kidney transplants

This article was originally published in Scrip

Executive Summary

Pharming's recombinant human C1 inhibitor product has been granted an investigational new drug (IND) application by the US FDA for preventing antibody-mediated rejection in kidney transplantation. The Netherlands-based biotech is to conduct clinical trials examining the product's impact on inflammatory damage and kidney graft loss, compared with current treatment. Pharming has also developed its recombinant human C1 inhibitor as Rhucin for hereditary angioedema. Rhucin has been received a negative opinion from the EU's CHMP, but the product is being developed with a view to US filing.

You may also be interested in...



Targacept/AstraZeneca Alzheimer's hope fails in Phase II

Targacept and AstraZeneca's investigational Alzheimer's disease drug ispronicline has failed to show improvement over placebo in a Phase IIb study.

Amgen reveals more details of denosumab's fracture benefit

Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.

GSK and Xenoport file restless legs drug Solzira in US

GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel